A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Phase 1 Completed 53 enrolled Bristol-Myers Squibb Exelixis · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule

Timeline

Start: 2008-07
Primary completion: 2014-04
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-833923	Small molecule	30 mg	Oral

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Summary

Timeline

Drugs

Indications